Related Experiment Video
Updated: Jan 10, 2026
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges
Khalil Choucair1, Hafsa Imtiaz1, Md Hafiz Uddin1
1Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA.
Abstract:
Activating KRAS mutations are highly relevant to various cancers, and KRAS is the most frequently altered oncogenic protein in solid tumors. While historically considered undruggable, two KRASG12C inactive state-selective inhibitors are currently approved for treating patients with non-small cell lung cancer. However, these agents only demonstrate a 30-40% response rate and a median progression-free survival of approximately 6 months, with the inevitable emergence of resistance mechanisms, hence remaining far from achieving a cure. Additionally, several cancers with poor prognostic outcomes, such as pancreatic adenocarcinoma, are driven by other non-G12C KRAS mutations and thus have no effective targeted therapies. Improvements in understanding RAS signaling, RNA, and nucleic acid chemistry, as well as the role of the tumor microenvironment, have sparked a paradigm shift in the approach to KRAS inhibition and suggested the potential for several novel combination therapies. In this review, we provide an overview of the RAS pathway and discuss the ongoing development and status of therapeutic strategies for targeting the oncogenic RAS. We further delve into the challenges of resistance mechanisms to better understand the rationale behind these developing strategies, describe their mechanisms of action, and offer insights into the current clinical trial status of each of these approaches.
Insights
Targeting KRAS mutations in cancer shows promise, but current therapies for KRAS G12C have limited efficacy and resistance. New strategies are exploring combination therapies for various KRAS mutations, including in pancreatic cancer.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Activating KRAS mutations are prevalent in solid tumors, historically posing a therapeutic challenge.
- Approved KRASG12C inhibitors offer modest response rates and are associated with resistance.
- Non-G12C KRAS mutations, common in pancreatic cancer, lack effective targeted treatments.
Purpose of the Study:
- To review the RAS signaling pathway and current therapeutic strategies targeting oncogenic RAS.
- To discuss emerging combination therapies and novel approaches for KRAS inhibition.
- To analyze resistance mechanisms and the clinical trial status of developing KRAS-targeted therapies.
Main Methods:
- Literature review of RAS pathway signaling and KRAS mutation-driven cancers.
- Analysis of current and investigational therapeutic strategies for KRAS inhibition.
- Examination of resistance mechanisms and their impact on treatment efficacy.
Main Results:
- Two KRASG12C inhibitors are approved but show limited efficacy and lead to resistance.
- Significant unmet need exists for targeting other KRAS mutations, particularly in pancreatic cancer.
- Advances in understanding RAS signaling and the tumor microenvironment enable novel combination therapies.
Conclusions:
- Despite progress, achieving a cure for KRAS-mutated cancers requires overcoming resistance and addressing diverse mutations.
- Novel combination therapies and a deeper understanding of resistance mechanisms are crucial for advancing KRAS-targeted treatment.
- Ongoing clinical trials are evaluating new strategies to improve outcomes for patients with KRAS-driven malignancies.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38The Ras Gene
Ras is a...
02:18Cancer
02:56Treatment Resistant Cancers
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...